ClinicalTrials.gg
CompletedNCT05817461Updated Jun 11, 2025

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

A Phase 1 interventional study of AZD0780 tablet and [14C]AZD0780 Solution for Infusion in Cardiovascular Diseases, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Study summary

The Sponsor is developing a new test medicine, AZD0780, with the aim to lower low-density lipoprotein cholesterol (LDL-C, fatty deposits) levels and cardiovascular (heart disease) risk, when given on top of standard care.

This two-part healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14; also referred as 14C) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

This study will take place at one non-NHS site, enrolling up to 8 male volunteers aged between 30 and 55 years.

Read the detailed description

The Sponsor is developing a new test medicine, AZD0780, with the aim to lower low-density lipoprotein cholesterol (LDL-C, fatty deposits) levels and cardiovascular (heart disease) risk, when given on top of standard care. High levels of LDL-C can build up on the walls of blood vessels, forming plaques which can increase the risk of heart disease and stroke.

This two-part healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body.

To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14; also referred as 14C) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

This study will take place at one non-NHS site, enrolling up to 8 male volunteers aged between 30 and 55 years.

In Part 1, volunteers will receive a single oral dose of AZD0780 on Day 1. The volunteers will then receive a single intravenous dose of [14C]AZD0780, 2.25 hours after the oral dose. Volunteers will be discharged on Day 8. Following a minimum 14 day washout period, all volunteers who participated in Part 1 of the study will be admitted to the clinical unit for Part 2. In Part 2, the volunteers will receive a single oral dose of [14C]AZD0780 on Day 1. Volunteers will be discharged on Day 11, however, if relevant radioactivity criteria have not been met, volunteers may need to remain at the clinical unit until Day 13. If relevant criteria have not been met at this point, home collections of urine and/or faeces may be required.

Volunteers will receive a follow up phone call between Day 18 and 21.

Volunteer's blood and urine and faeces will be taken throughout the study for analysis of the test medicine and for their safety.

Volunteers are expected to be involved in this study for 10 weeks from screening to the follow up call.

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • Dyslipidaemia
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 8 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Must be willing and able to communicate and participate in the whole study.
  • Healthy male subjects aged 30 to 55 years inclusive at the time of signing informed consent.
  • Must agree to adhere to the requirements defined in the Clinical Protocol
  • (BMI) between 18.0 and 32.0 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder (e.g. cardiovascular, pulmonary, GI, liver, renal, neurological, musculoskeletal ,endocrine, metabolic, malignant, psychiatric, major physical impairment, skin abnormalities and glucose metabolism abnormalities) which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  • History or presence of clinically significant GI, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0780. Hay fever is allowed unless it is active.
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  • Evidence of current SARS-CoV-2 infection
  • Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are not allowed.
  • Clinically significant abnormal findings in vital signs, at screening or admission, as judged by the investigator.
  • Clinically significant abnormalities on 12-lead , at screening or admission, as judged by the investigator.
  • Any positive result on screening for serum surface antigen (HBsAg), antibody (HCV Ab), and (HIV) 1 and 2 antibody
  • Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<80 mL/min using the Cockcroft-Gault equation
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer. Note: subjects consented and screened, but not randomised in this study or a previous Phase I study, are not excluded.
  • Subjects who report to have previously received AZD0780.
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  • Subjects who have been administered IMP in an ADME study in the last 12 months.
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than 4 g of paracetamol/acetaminophen per day), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the two weeks prior to the first administration of IMP or longer if the medication has a long half-life. COVID-19 vaccines are accepted concomitant medications. Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the is such that no PD activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks or 5 half-lives, whichever is longer, prior to the first administration of IMP.
  • Known or suspected history of alcohol or drug abuse in the past 2 years or excessive intake of alcohol (>21 units per week [1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type]) or as judged by the investigator.
  • A confirmed positive alcohol breath test at screening or admission.
  • Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.
  • A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  • Confirmed positive drugs of abuse test result at screening or admission.
  • Excessive intake of caffeine-containing drinks or food (e.g. coffee, tea, chocolate) as judged by the investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (e.g. >5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the site.
  • Subjects with pregnant or lactating partners
  • Planned in-patient surgery, dental procedure or hospitalisation during the study.
  • Involvement of any Astra Zeneca, Quotient or study site employee or their close relatives.
  • Judgment by the investigator that the volunteer should not participate in the study if they have any ongoing or recent (i.e. during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Subjects who cannot communicate reliably with the investigator.
  • Vulnerable subjects, e.g. kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AZD0780

    In Part 1, one oral dose of AZD0780 and one intravenous dose of \[14C\]AZD0780. In Part 2, one oral dose of \[14C\]AZD0780

    Drug: AZD0780 tablet · Drug: [14C]AZD0780 Solution for Infusion · Drug: [14C]AZD0780 Oral Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability (F) - Part 1

    Absolute bioavailability based on AUC0-inf of oral formulation compared to IV adjusted for dose

    Time frame: Plasma sample collection from pre-dose to 168 hours post-dose

  2. Area under the curve from time 0 extrapolated to infinity for AZD0780 and total radioactivity (AUC0-inf) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  3. Time to maximum concentration (tmax) for AZD0780 and total radioactivity - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  4. Maximum observed concentration (Cmax) for AZD0780 and total radioactivity - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  5. Area under the curve from time 0 to the time of last measurable concentration for AZD0780 and total radioactivity (AUC0-t) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  6. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) and total radioactivity - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  7. Terminal elimination half-life for AZD0780 (t1/2) and total radioactivity - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  8. First order rate constant associated with the terminal (log-linear) portion of the curve for AZD0780 (λz) and total radioactivity - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  9. Total body clearance calculated after a single IV administration (CL) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  10. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  11. Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration (Vz) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  12. Volume of distribution at steady state after a single IV administration (Vss) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  13. Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) - Part 1

    PK of AZD0780 and \[14C\]AZD0780 in plasma

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  14. Amount of AZD0780 excreted (Ae) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  15. Amount of AZD0780 excreted expressed as a fraction of dose excreted (%Ae) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  16. The cumulative amount of AZD0780 exreted (CumAe) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  17. Cumulative amount of AZD0780 excreted expressed as a fraction of dose excreted (Cum%Ae) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD0780 in urine and faecal samples

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  18. Time to maximum concentration (tmax) for AZD0780 and total radioactivity - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  19. Maximum observed concentration (Cmax) for AZD0780 and total radioactivity - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  20. Area under the curve from time 0 to the time of last measurable concentration for AZD0780 and total radioactivity (AUC0-t) - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  21. Area under the curve from time 0 extrapolated to infinity for AZD0780 and total radioactivity (AUC0-inf) - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  22. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) and total radioactivity - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  23. Terminal elimination half-life for AZD0780 (t1/2) and total radioactivity - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  24. First order rate constant associated with the terminal (log-linear) portion of the curve for AZD0780 (λz) and total radioactivity - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  25. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  26. Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

  27. Renal clearance calculated using plasma AUC (CLR) - Part 2

    PK of AZD0780 in urine and faeces

    Time frame: Urine and faecal samples collected from pre-dose until 240 hours post-dose

Secondary outcomes

  1. Number of subjects with treatment-related adverse events - Part 1 and Part 2

    To provide additional safety and tolerability information for AZD0780 by assessing the incidence of AEs

    Time frame: Through study duration, an average of 10 weeks

  2. Blood:plasma concentration ratios - Part 2

    Blood:plasma concentration ratios of total radioactivity

    Time frame: Whole blood samples and plasma samples collected from pre-dose until 240 hours post-dose

  3. Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating TR (plasma) or accounting for 10% or more of the dose in urine and faeces - Part 2

    Metabolite profiling and structural identification from plasma, urine and faecal samples. Metabolites are to be reported in a separate report after the Clinical Study Report is final.

    Time frame: Plasma, urine and faecal samples collected from pre-dose until 240 hours post-dose

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2023, 1 month.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 1 month is below that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Apr 18, 2023
StartActual
Apr 19, 2023
Primary completionActual
Jun 6, 2023
CompletionActual
Jun 6, 2023
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05817461
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 19, 2023
Primary completion
Jun 6, 2023
Completion
Jun 6, 2023
Last update
Jun 11, 2025

Study contacts

Somasekhara Menakuru, MBBS, MS, MRCS, DPM, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion